- In May 2024, NovaResp Technologies successfully raised USD 3 million in a seed extension round to advance clinical trials for its cMAP positive airway pressure (PAP) software. This funding will expedite the development of their innovative solution, designed to enhance the effectiveness of sleep apnea treatments. This development aligns with the ongoing innovation in the sleep apnea devices market, reflecting the growing investment in technologies aimed at improving patient outcomes and expanding treatment options for sleep apnea
- In February 2024, EnsoData received FDA approval for its AI-powered EnsoSleep algorithm, designed to improve the diagnosis of sleep disorders. This approval strengthens the algorithm's ability to provide accurate and efficient assessments of sleep conditions through advanced artificial intelligence technology. This development highlights the growing role of artificial intelligence in the global sleep apnea devices market, as AI-driven solutions increasingly enhance diagnostic accuracy and streamline the assessment process
- In February 2024, researchers at Mount Sinai secured USD 4 million in funding to develop and evaluate AI-powered models designed to predict adverse outcomes in obstructive sleep apnea. This initiative seeks to enhance patient care by utilizing advanced AI technologies to improve diagnosis and risk assessment. By leveraging AI to predict patient outcomes more accurately, this research has the potential to revolutionize sleep apnea management, driving the demand for innovative diagnostic and therapeutic devices within the market
- In November 2023, Vivos Therapeutics received FDA 510(k) clearance for its CARE (Complete Airway Repositioning and/or Expansion) oral devices, specifically designed for adults suffering from severe obstructive sleep apnea (OSA). This approval includes the company's key DNA, mRNA, and mmRNA oral appliances, representing a significant milestone in expanding the range of treatment options for OSA patients. This development highlights the ongoing innovation within the global sleep apnea devices market, with Vivos Therapeutics contributing to the diversification of treatment modalities
- In October 2023, ResMed entered into a strategic partnership with Bittium Biosignals Ltd, a subsidiary of Bittium Corporation, to distribute the Bittium Respiro, an advanced home sleep apnea testing and analysis solution. The agreement encompasses the Respiro measuring device, accessories, and the Respiro Analyst software platform, covering key markets including Norway, the UK, Switzerland, Ireland, Finland, and Sweden. This collaboration underscores the growing demand for home-based sleep apnea diagnostic solutions, enhancing the accessibility and convenience of sleep apnea testing
